Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BMS-986528

PreclinicalSmall molecule

Bristol-Myers Squibb

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Arthritis, RheumatoidRecruiting

Arthritis, RheumatoidPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Arthritis, Rheumatoid

NCT07412704

Clinical

Trials by Indication[1]

Arthritis, Rheumatoid1 trial

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07412704·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986528. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986528 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986528. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

Related News